EMENDO BIOTHERAPEUTICS
Emendo was set up to expand what is possible in genome editing. They believe that challenges can be overcome by fusing expertise in diverse disciplines, and by looking at the core questions with a new approach. Having studied at top academic institutions, including the Weizmann Institute, Emendo’s founders came together to pool their collective knowledge of protein engineering and DNA repair to achieve a shared goal: the creation of genetic medicines that deliver on the promise of gene editing... . By transforming the available tools, they are able to address those disorders and diseases that are currently considered to be untreatable. Working at the cutting edge of gene editing, the Emendo team combines knowledge, expertise and proven scientific methodologies, with creativity, ingenuity and daring to push the boundaries and achieve more.
EMENDO BIOTHERAPEUTICS
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2015-05-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.emendobio.com
Total Employee:
11+
Status:
Active
Total Funding:
61 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network
Similar Organizations
DNX Biotherapeutics
DNX Biotherapeutics is a Biotechnology company.
Current Employees Featured
David Baram President & CEO @ Emendo Biotherapeutics
President & CEO
2015-05-01
Asael Herman CTO @ Emendo Biotherapeutics
CTO
Lior Izhar CTO @ Emendo Biotherapeutics
CTO
2021-08-01
Todd Wider Chairman & Chief Medical Officer @ Emendo Biotherapeutics
Chairman & Chief Medical Officer
Shilo Ben Zeev Co Founder & Board Member @ Emendo Biotherapeutics
Co Founder & Board Member
2015-05-01
Founder
Investors List
AnGes
AnGes investment in Series B - Emendo Biotherapeutics
Takeda Ventures
Takeda Ventures investment in Series B - Emendo Biotherapeutics
Official Site Inspections
http://www.emendobio.com Semrush global rank: 5.54 M Semrush visits lastest month: 1.53 K
- Host name: 87.186.102.34.bc.googleusercontent.com
- IP address: 34.102.186.87
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Emendo Biotherapeutics"
EmendoBio, Inc. - Crunchbase Company Profile
View contacts for EmendoBio, Inc. to access new leads and connect with decision-makers.See details»
EmendoBio | Our Story
Bringing together bold scientists across the fields of computational biology, protein engineering, and RNA guide design, we have relentlessly focused on overcoming the existing limitations of CRISPR-based genome editing to …See details»
EmendoBio, Inc. - Funding, Financials, Valuation & Investors
In funding over 3 rounds. Their latest funding was raised on Dec 15, 2020 from a Corporate Round round. EmendoBio, Inc. is funded by 3 investors. AnGes and AnGes are the most …See details»
EmendoBio, Inc. - Contacts, Employees, Board Members
EmendoBio, Inc. has 4 current employee profiles, including President & CEO David Baram.See details»
EmendoBio - BIO International Convention | BIO
The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services.See details»
EmendoBio ǀ Our Services
Consulting services EmendoBio is an expert in gene editing with vast experience in the discovery of novel nucleases, engineering them, and development of CRISPR based gene editing …See details»
Japan’s AnGes Acquires EmendoBio, Eying High ... - GeneOnline …
Dec 17, 2020 This transaction positions AnGes to expand its pipeline and partnerships and introduce gene editing capabilities by leveraging EmendoBio’s proprietary platforms, team of …See details»
EMENDO - EmendoBio Inc. Trademark Registration
Mark For: EMENDO™ trademark registration is intended to cover the categories of enzymes for scientific and research purposes; nucleases and nuclease panels for scientific and research …See details»
Emendo Biotherapeutics, Inc. (Emendo Biotherapeutics, Inc.) - 药物 …
With recent achievements including the licensing agreement for use of EmendoBio’s novel gene editing technology, and by securing GMP license for the largest cell-therapy manufacturing …See details»
Company: Emendo Biotherapeutics - CRISPR Medicine
Emendo Biotherapeutics is a next-generation gene-editing company focused on developing novel nucleases for its proprietary CRISPR systems. The nucleases are being developed for …See details»
Emendo Biotherapeutics - Craft
Emendo Biotherapeutics is a biotechnology company that develops gene-editing tools for genetic disorders. It uses protein engineering and selection platforms to provide allele-specific editing, …See details»
License agreement with Anocca AB for EmendoBio's gene editing ...
Mar 26, 2024 “Integrating EmendoBio’s technology into our manufacturing process supports Anocca’s aim of generating the highest-quality cell therapy products. This next-generation …See details»
EmendoBio | Our Approach
At EmendoBio, we do not believe in a one solution fits all gene editing approach. We believe the pathway to curing diseases is a tailor-made custom solution per target. The foundation of our …See details»
AnGes acquires EmendoBio, Inc. - 2020-12-15 - Crunchbase
Dec 15, 2020 AnGes acquires EmendoBio, Inc. on 2020-12-15 for $250000000See details»
Emendo Biotherapeutics 2025 Company Profile: Valuation
Information on acquisition, funding, cap tables, investors, and executives for Emendo Biotherapeutics. Use the PitchBook Platform to explore the full profile.See details»
Emendo Biotherapeutics Leaders Share Expert Insights on Cutting …
Sep 28, 2023 For more information on EmendoBio and its growing pipeline, visit: emendobio.com About Emendo Biotherapeutics EmendoBio is a next-generation CRISPR …See details»
Anocca to license EmendoBio's gene editing technology
Mar 15, 2024 Anocca has entered a licensing agreement with EmendoBio for the use of the latter’s OMNI-A4 nuclease, a gene editing technology.See details»
EmendoBio | Our Science | Pipeline
EmendoBio has a diverse program portfolio in different stages of clinical development.See details»
Federal government announces support for cutting-edge, AI- and …
18 hours ago OmniaBio Inc. is a technology-focused, global cell and gene therapy contract development and manufacturing organization. A subsidiary of the Centre for …See details»
EmendoBio | Our Science
EmendoBio's novel approach to engineering nucleases creates a custom fit design per disease achieving single-allele editing strategies for the severest indications.See details»